International scheduling Australia's Therapeutic Goods Administration (interim decision, April 2024) and New Zealand's Medsafe (Medicines Classification Committee, June 2025) have moved to schedule BPC-157 as a prescription-only medicine, despite its unavailability through legitimate prescription
Yet, despite its crucial role, it often remains shrouded in mystery
Clinical oversight is provided by Dr
However, the largest Phase IIb trial involving 536 participants failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading to development termination in 2007
Targets the gut lining directly
Its vital for maintaining healthy nerve and blood cells and is often prescribed to address B12 deficiencies leading to fatigue and weakness